AndreaBozzo/ceres-open-data-index huggingface dataset:
Development of dengue virus replicons expressing HIV-1 gp120 and other heterologous genes: a potential future tool for dual vaccination against dengue virus and HIV

Background
          Toward the goals of providing an additional vector to add to the armamentarium available to HIV vaccinologists and of creating a bivalent vaccine effective against dengue virus and HIV, we have attempted to create vectors which express dengue virus non-structural proteins and HIV immunogens. Previously we reported the successful construction of dengue virus replicons which lack structural genes necessary for virion release and spreading infection in culture but which can replicate intracellularly and abundantly produce dengue non-structural proteins. Here we attempted to express heterologous genetic material from these replicons.
        
        
          Results
          We cloned into a Δpre-M/E dengue virus replicon genes for either green fluorescent protein (GFP), HIV gp160 or HIV gp120 and tested the ability of these constructs to express dengue virus proteins as well as the heterologous proteins in tissue culture after transfection of replicon RNA.
        
        
          Conclusions
          Heterologous proteins were readily expressed from these constructs. GFP and gp120 demonstrated minimal or no toxicity. Gp160 expressing replicons were found to express proteins abundantly at 36 hours post transfection, but after 50 hrs of transfection, few replicon positive cells could be found despite the presence of cellular debris positive for replicon proteins. This suggested that gp160 expressed from dengue virus replicons is considerably more toxic than either GFP or gp120. The successful expression of heterologous proteins, including HIV gp120 for long periods in culture suggests this vector system may be useful as a vaccine vector, given appropriate delivery methods.
Prenatal diagnosis of Caudal Regression Syndrome : a case report

Background
          Caudal regression is a rare syndrome which has a spectrum of congenital malformations ranging from simple anal atresia to absence of sacral, lumbar and possibly lower thoracic vertebrae, to the most severe form which is known as sirenomelia. Maternal diabetes, genetic predisposition and vascular hypoperfusion have been suggested as possible causative factors.
        
        
          Case presentation
          We report a case of caudal regression syndrome diagnosed in utero at 22 weeks' of gestation. Prenatal ultrasound examination revealed a sudden interruption of the spine and "frog-like" position of lower limbs. Termination of pregnancy and autopsy findings confirmed the diagnosis.
        
        
          Conclusion
          Prenatal ultrasonographic diagnosis of caudal regression syndrome is possible at 22 weeks' of gestation by ultrasound examination.
Compound 526888: Triethylene glycol, pentyl ether, acetate

Chemical compound data from PubChem database. IUPAC Name: 2-[2-(2-pentoxyethoxy)ethoxy]ethyl acetate. Molecular Formula: C13H26O5. Molecular Weight: 262.34. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Treatment of established postoperative nausea and vomiting: a quantitative systematic review

Background
          The relative efficacy of antiemetics for the treatment of postoperative nausea and vomiting (PONV) is poorly understood.
        
        
          Methods
          Systematic search (MEDLINE, Embase, Cochrane Library, bibliographies, any language, to 8.2000) for randomised comparisons of antiemetics with any comparator for the treatment of established PONV. Dichotomous data on prevention of further nausea and vomiting, and on side effects were combined using a fixed effect model.
        
        
          Results
          In seven trials (1,267 patients), 11 different antiemetics were tested without placebos; these data were not further analysed. Eighteen trials (3,809) had placebo controls. Dolasetron 12.5–100 mg, granisetron 0.1–3 mg, tropisetron 0.5–5 mg, and ondansetron 1–8 mg prevented further vomiting with little evidence of dose-responsiveness; with all regimens, absolute risk reductions compared with placebo were 20%–30%. The anti-nausea effect was less pronounced. Headache was dose-dependent. Results on propofol were contradictory. The NK1 antagonist GR205171, isopropyl alcohol vapor, metoclopramide, domperidone, and midazolam were tested in one trial each with a limited number of patients.
        
        
          Conclusions
          Of 100 vomiting surgical patients receiving a 5-HT3 receptor antagonist, 20 to 30 will stop vomiting who would not have done so had they received a placebo; less will profit from the anti-nausea effect. There is a lack of evidence for a clinically relevant dose-response; minimal effective doses may be used. There is a discrepancy between the plethora of trials on prevention of PONV and the paucity of trials on treatment of established symptoms. Valid data on the therapeutic efficacy of classic antiemetics, which have been used for decades, are needed.
Patent AT-E400228-T1: [Translated] LOCKING NAIL FOR THE TREATMENT OF FEMUR SHAFT FRACTURES

The locking nail for the repair of femur shaft fractures, also in connection with trochanteric femur fractures, comprises a proximal nail section (2) and a distal nail section (3) adjoining the latter, with the nail sections (2, 3) having bores (2e, 2f, 2h, 2i, 3a, 3b, 3c) for the reception of bone screws, and with the distal nail section (3) having a curvature extending in an anterior-posterior plane (apE) and corresponding substantially to the antecurvature of the femur, with the proximal nail section (2) having at least over a partial section (2a, 2b) a continuous curvature, in particular with constant radius of curvature (R2), extending in a lateral-medial plane (lmE).
Compound 529356: Ethyl 2-(3-([(2,5-dimethoxyphenyl)sulfonyl]amino)-4-methylphenoxy)propanoate

Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] 2-(2-methylpropoxycarbonylamino)propanoate. Molecular Formula: C14H29NO4Si. Molecular Weight: 303.47. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401043-T1: [Translated] ENDOLUMINAL DEVICE WITH IMPROVED ENDOTHELIALIZATION AND PRODUCTION METHOD THEREOF

An implantable endoluminal device which is fabricated from materials which present a blood or body fluid and tissue contact surface which has controlled heterogeneities in material constitution. An endoluminal stent which is made of a material having controlled heterogeneities in the stent material along the blood flow surface of the stent and the method of fabricating the stent using vacuum deposition methods.
Patent AT-E399575-T1: [Translated] CATHETER AND GUIDEWIRE EXCHANGE SYSTEM

A catheter and guide wire exchange system including a catheter having a guide wire lumen with a guide way extending along the length of a stiffened proximal shaft portion, and a guide member slidably disposed about the proximal shaft for directing a guide wire into or out of the guide way and the guide wire lumen. The guide member may be slid along the proximal shaft portion and the guide wire in zipper-like fashion so that the guide wire is contained within the guide wire lumen distal to the guide member and with the guide wire and catheter being separated proximal of the guide member.
Blood substitutes: Haemoglobin therapeutics in clinical practice

Early approaches to the development of oxygen carriers involved the			 use of stroma-free hemoglobin solutions. These solutions did not require blood			 typing or crossmatching and could be stored for long periods. In addition, a			 variety of methods have been developed in chemically modifying and stabilizing			 the hemoglobin molecule. Several hemoglobin therapeutics are now in clinical			 trials as temporary alternatives to blood or as therapeutic agents for			 ischemia. The various hemoglobin products under development are derived from			 three principal sources: human, bovine and genetically engineered hemoglobin.			 Diaspirin cross-linked hemoglobin (DCLHb), administered at doses ranging from			 approximately 20-1000 ml, has been investigated in a number of clinical trials			 in patients undergoing orthopedic, abdominal aortic repair, major abdominal			 surgery, cardiac surgery and in critically ill patients with septic shock. In			 several studies, DCLHb was effective in avoiding the transfusion. However,			 Baxter Healthcare Corporation (Chicago, Illinois, USA) stopped the development			 of DCLHb after two unsuccessful trials in trauma patients. Bovine polymerized			 hemoglobin has also been extensively studied. Several phase II and phase III			 trials have been performed with this product in hemorrhagic surgery, cardiac			 surgery and vascular surgery, but data have not yet been published. Hemoglobin			 therapeutics could provide an important new option as an alternative to blood			 transfusion. Furthermore, they may be able to provide an immediate on-site			 replacement for traumatic blood loss, prevent global ischemia and organ			 failure, treat focal ischemia, and provide effective hemodynamic support for			 septic shock-induced hypotension.
Patent AT-E400281-T1: [Translated] VAGINAL LACTOBACILLUS MEDICATION

Disclosed are novel isolated strains of bacteria of the genus Lactobacillus which are useful in a vaginal medicant. Also disclosed are medicants containing such Lactobacilli, a novel preservation matrix for microorganisms, a method for preserving microbial cells within a medicant, and methods for preventing and treating vaginal and gastrointestinal infections.
The National Survey of Child and Adolescent Well-Being I (NSCAW I), General Release, Waves 1-5

The target population for the NSCAW includes all children and families that enter the child welfare system. Two samples were drawn from the population in 92 participating county child welfare agencies throughout the nation. The CPS sample includes 5,501 children, who were between the ages of 0 and 14 years at the close of the investigation. All investigations for the sample were closed between October 1, 1999 and December 31, 2000. The second sample consists of an additional 727 children, who were in out-of-home care for about 12 months at the time of sampling. This second group, referred to as the One Year in Foster Care (OYFC) Sample, was selected to allow special analysis related to the experience of out-of-home care. Waves 2, 3, and 4 take place 12, 18, and 36 months after the close of the investigation.

Investigators: Research Triangle Institute
SHIP Children with Elevated Blood Lead Levels 2009-2020

This is historical data. The update frequency has been set to "Static Data" and is here for historic value. Updated on 8/14/2024

Children with Elevated Blood Lead Levels - "Lead is a toxic metal that has no safe level. Children are especially sensitive to lead exposure. The legal definition of an elevated blood lead level in Maryland is 10 micrograms/deciliter (mcg/dL), but the current CDC and Maryland guidelines for health care providers urge follow up for any child with a level of 5 mcg/dL or higher.  Children most often are exposed to lead if they swallow dust containing lead paint, usually when there is peeling, flaking, or chipping lead paint or from home renovation. Maryland health care providers are now supposed to test all children born on or after January 1, 2015 at their 12 and 24 month well child visits.  <a href = "https://health.maryland.gov/pophealth/Documents/SHIP/SHIP%20Lite%20Data%20Details/Children%20with%20Elevated%20Blood%20Lead%20Levels.pdf" > Link to Data Details </a>
"
Behavioral Health Barometer: New Hampshire, 2014

This is a behavioral health report for the state of New Hampshire. It uses the  National Survey on Drug Use and Health (NSDUH) and the National Survey of Substance Abuse Treatment Services (NSSATS) to address the topics of youth substance use , youth mental health and treatment, adult mental health and treatment, substance use, substance use treatment, and medicare enrollees for the years 2009 to 2013.
2010 State Profile — Florida

This state profile includes data from facilities in Florida that reported to N-SSATS for the survey reference date March 31, 2010. Data were collected on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (both public and private) in Florida. In Florida, 593 substance abuse treatment facilities were included in the 2010 N-SSATS, reporting that there were 49,002 clients in substance abuse treatment on March 31, 2010. The survey response rate in Florida was 86.9%.
Estradiol and norethindrone acetate

Estradiol and Norethindrone Acetate is a prescription oral tablet combining estrogen (estradiol) and progestin (norethindrone acetate) to help manage menopause symptoms like hot flashes and prevent bone loss. Each tablet contains 1 mg estradiol and 0.5 mg norethindrone acetate, manufactured by Naari Pte. Limited as a generic version. This information was generated using AI and is provided for informational and research purposes only.
Thyroxine signal transduction in liver cells involves phospholipase C and phospholipase D activation. Genomic independent action of thyroid hormone

Background
          Numerous investigations demonstrate a novel role of thyroid hormone as a modulator of signal transduction. Protein kinase C (PKC) is critical to the mechanism by which thyroid hormones potentiate both the antiviral and immunomodulatory actions of IFNγ in different cells and regulate the exchange of signalling phospholipids in hepatocytes. Because nothing is known about accumulation of PKC modulator - diacylglycerol in cells treated with T4, we examined the nongenomic effect of thyroid hormones on DAG formation and phospholipase activation in liver cells.
        
        
          Results
          The results obtained provide the first demonstration of phospholipase C, phospholipase D and protein kinase C nongenomic activation and diacylglycerol (DAG) accumulation by L-T4 in liver cells. The experiments were performed in either the [14C]CH3COOH-labeled rat liver slices or isolated hepatocytes pre-labeled by [14C]oleic acid. L-T4 activates the DAG production in a concentration- and time-dependent manner. DAG formation in stimulated cells is biphasic and short-lived event: there is an initial, rapid rise in DAG concentration and then a slower accumulation that can be sustained for a few minutes. The early phase of L-T4 generated DAG only is accompanied by phosphatidylinositol 4,5-bisphosphate level decrease and inositol 1,4,5-trisphosphate formation while the second phase is abolished by PKC inhibitor l,(5-isoquinolinesulphonyl)2methylpiperasine dihydrochloride (H7) and propranolol. The second phase of DAG production is accompanied by free choline release, phosphatidylcholine content drop and phosphatidylethanol (Peth) formation. Inhibitor of phospholipase-C-dependent phosphoinositide hydrolysis, neomycin sulfate, reduced the Peth as well as the DAG response to L-T4.
        
        
          Conclusions
          The present data have indicated the DAG signaling in thyroid hormone-stimulated liver cells. L-thyroxine activates a dual phospholipase pathway in a sequential and synchronized manner: phospholipase C initiates the DAG formation, and PKC mediates the integration of phospholipase D into the signaling response during the sustained phase of agonist stimulation.
Compound 528213: Benzoic acid, 2-hydroxy-6-methoxy, DTBS

Chemical compound data from PubChem database. IUPAC Name: 2,2-ditert-butyl-5-methoxy-1,3,2-benzodioxasilin-4-one. Molecular Formula: C16H24O4Si. Molecular Weight: 308.44. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Weekly Cumulative Estimated Number of RSV Vaccinations Administered in Retail Pharmacies and Physicians’ Medical Offices, Adults 60 to 74 Years and 75 years and older, United States

•Weekly Cumulative Estimated Number of RSV Vaccinations Administered in Retail Pharmacies and Physicians’ Medical Offices, Adults 60 to 74 Years and 75 Years and Older, United States  

• Estimated Number of RSV vaccinations among adults 60 years and older is assessed through IQVIA (https://www.iqvia.com/) as a source of information on vaccinations administered in retail pharmacies (include chain, mass merchandise, food stores, and independent pharmacies) and physician medical offices.
Patent AT-E401632-T1: [Translated] SYSTEM AND METHOD FOR REMOTE MAINTENANCE OF THE ELECTRONIC DEVICES OF VEHICLES AND IN PARTICULAR THE ELECTRONIC BRAKE ARRANGEMENTS OF INDUSTRIAL VEHICLES

The system has two electronic maintenance devices (1, 2) designed for remote conversation via a telecommunication network (3) such that the device (2) permits to perform remote maintenance of an electronic equipment of a vehicle, in local communication with the device (1). The remote maintenance is performed with the help of a maintenance program corresponding to the equipment, where the program is stored in a memory of the device (1). An independent claim is also included for a method of maintenance of an electronic equipment of a vehicle.
3.4 Clients under age 18 in treatment by type of care received, and clients under age 18 in treatment in facilities offering special programs or groups for adolescents: 2007-2011.Number and percent distribution

This a National Survey of Substance Abuse Treatment Services (N-SSATS) data table showing clients under age 18 in treatment by type of care received, and clients under age 18 in treatment in facilities offering special programs or groups for adolescents from 2007 to 2011.
Compound 529621: beta-Calacorene

Chemical compound data from PubChem database. IUPAC Name: 7-methyl-4-methylidene-1-propan-2-yl-2,3-dihydro-1H-naphthalene. Molecular Formula: C15H20. Molecular Weight: 200.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530141: Glycine, N-(trimethylsilyl)-, trimethylsilyl ester

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 2-(trimethylsilylamino)acetate. Molecular Formula: C8H21NO2Si2. Molecular Weight: 219.43. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Molecular genetics and structural genomics of the human protein kinase C gene module

Background
          Protein kinase C (PKC) has become a major focus among cell biologists interested in second-messenger signal transduction and much has been learned about differences in the cellular localization and function of its different isotypes. In this study we systematically address the genomic locations and gene structures of the human PKC gene module.
        
        
          Results
          We first carried out fine chromosomal mapping of all nine PKC genes by fluorescence in situ hybridization (FISH), using cosmid and BAC probes. The PKC genes are found to be dispersed throughout the genome, and in some positions distinct from those previously reported: PKCα is at 17q24, PKCβ at 16p12, PKCγ at 19q13.4, PKCδ at 3p21.2, PKCε at 2p21, PKCζ at 1p36.3, PKCη at 14q22-23, PKCθ at 10p15 and PKCι at 3q26. For PKCι, an additional FISH signal mapped on Xq21.3 revealed a pseudogene (derived by retrotransposition). PKCγ, ζ, and θ are found to map to the most distal positions on the chromosomes, potentially implicating telomere position effects in their expression. Using the complete human genome draft sequence and bioinformatics tools, we then carried out a systematic analysis of PKC gene structure, including determination of the occurrence of single-nucleotide polymorphisms corresponding to the PKC loci.
        
        
          Conclusion
          This resource of genomic information now facilitates investigation of the PKC gene module in structural chromosomal abnormalities and human disease locus mapping studies.
Compound 527808: Benzoic acid, 3-chloro, octyl ester

Chemical compound data from PubChem database. IUPAC Name: octyl 3-chlorobenzoate. Molecular Formula: C15H21ClO2. Molecular Weight: 268.78. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
COVID-19 State Profile Report - Louisiana

<b>After over two years of public reporting, the State Profile Report will no longer be produced and distributed after February 2023. The final release was on February 23, 2023. We want to thank everyone who contributed to the design, production, and review of this report and we hope that it provided insight into the data trends throughout the COVID-19 pandemic.
Data about COVID-19 will continue to be updated at <a href='https://covid.cdc.gov/covid-data-tracker/#datatracker-home' >CDC’s COVID Data Tracker</a>.
 </b>

<p>
The State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level.
 </p>

It is a weekly snapshot in time that:
<ul>
<li>Focuses on recent outcomes in the last seven days and changes relative to the month prior</li>
<li>Provides additional contextual information at the county level for each state, and includes national level information</li>
<li>Supports rapid visual interpretation of results with color thresholds</li>
</ul>
2011 NSSATS - Data on Substance Abuse Treatment Facilities

This report presents results from the 2011 National Survey of Substance Abuse Treatment Services (N-SSATS), an annual census of facilities providing substance abuse treatment. Conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA), N-SSATS is designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 States, the District of Columbia, Guam, Puerto Rico, Virgin Islands, and Republic of Palau.
New York State Statewide COVID-19 Admissions by Gender (Archived)

<b>Note:</b> Data elements were retired from HERDS on 10/6/23 and this dataset was archived.

This dataset includes information at the report date level on patients admitted for inpatient care to the hospital that are lab-confirmed COVID-19 positive.  Admitted means that the patient was newly admitted to the hospital or was confirmed positive after admission.  Gender information became available for COVID-19 admissions as of May 2, 2020.  Hospitalized means patients admitted as inpatients in either inpatient or observation beds and does not include patients that were treated and released from an Emergency Department. The title of this dataset was initially the Hospital Electronic Response Data System (HERDS) Hospital Survey: COVID-19 Admissions by Gender. The dataset was changed to its current title on 11/4/2021.